A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made huge purchases on Tuesday. Altogether, these funds bought over 850,000 shares of UiPath Inc. (NYSE: PATH) on Tuesday, as the price of these ETFs gained less than 1% on Tuesday. Note that these funds are still up handily in the last year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 291,229 shares of UiPath, and ARK Innovation ETF (NYSEARCA: ARKK) bought 566,900 shares. At Tuesday’s closing price, this would have valued these purchases at roughly $59.1 million. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 84% in the past year and ARKK is up 92%.

Check out all of ARK Invest’s buys for Tuesday:

Fund	Ticker	Company	Shares
ARKG	IONS	Ionis Pharmaceuticals	268,748
ARKG	PATH	UIPath	291,229
ARKK	PATH	UIPath	566,900
ARKQ	KTOS	Kratos Defense & Security Solutions	50,625
ARKQ	BZ	Kanzhun	109,718
ARKW	BZ	Kanzhun	101,005
ARKW	VUZI	Vuzix	232,063

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use